FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
106 letters match. Newest first.
-
DrugsGenoGenix LLC
FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.
High risk -
DrugsBoothwyn Pharmacy, LLC
Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
High risk -
DevicesPalamur Biosciences Private Limited
FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.
High risk -
DrugsDarmerica, LLC
FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.
High risk -
DrugsFWD Care, Inc. dba FWD
FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.
Medium -
DrugsExpert Aesthetics
FDA warned Expert Aesthetics over website claims that its compounded semaglutide and tirzepatide are generic Ozempic and Mounjaro.
Low -
DrugsHealthy Living Clinic
FDA warned Healthy Living Clinic that its website misbrands compounded semaglutide by comparing it to Wegovy, Ozempic, and Rybelsus.
Low -
DrugsHims & Hers Health, Inc. dba Hers
FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.
Medium -
DrugsAmazing Meds
FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
High risk -
DrugsGenLabMeds
GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.
High risk -
DrugsFitRX, LLC dba Zealthy
FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.
Medium -
DrugsLovely Meds, Inc. dba Lovely Meds
FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.
Low -
DrugsThe HCG Institute
FDA warns The HCG Institute over misleading claims for compounded semaglutide sold online.
High risk -
DrugsVitals RX
FDA warned telehealth seller Vitals RX that its website falsely implies compounded semaglutide and tirzepatide are the approved drug Ozempic.
Medium -
DrugsTuyo Health, Inc. dba Tuyo Health
FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.
Medium -
DrugsJulyMD
FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.
High risk -
DrugsSlendid
FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.
Medium -
DrugsSprout Health Partners LLC dba Sprout Health
FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.
Low -
DrugsMaster Pharmaceuticals Group
FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.
High risk -
DrugsTRYM Health, Inc. dba TRYM Health
FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
Medium -
Drugsinspire.clinic
FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.
Low -
DrugsBioverse, Inc. dba Bioverse
FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.
Low -
DrugsElevate Your Wellness LLC, dba Elevated
FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.
Low -
DrugsCosmo Medical Spa dba Cosmo Med Spa
FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.
Medium -
Drugsdirectmeds.com, Inc. dba DirectMeds
FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsMane & Steel, LLC. dba Mane & Steel
FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.
Low -
DrugsLumimeds
FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsBody Good Studio
FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.
High risk -
DrugsAll American Wellness
FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.
Low -
DrugsHealthy Male
FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.
Low -
DrugsIntimate Rose
FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.
High risk -
DrugsCurex
FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.
High risk -
DrugsHealthon Inc. dba Healthon
FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.
High risk -
DrugsNovo Nordisk Inc.
FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.
Low -
DevicesJiangsu Kerbio Medical Technology Group Co.
FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.
High risk -
DevicesCCIC Huatongwei International Inspection Co., Ltd.
FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.
High risk -
DrugsUSApeptide.com
FDA warns Germany-based USApeptide.com that it sells unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers online.
High risk -
DrugsPrime Vitality, Inc. dba Prime Peptides
FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.
High risk -
DrugsSwisschems
Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.
High risk -
DrugsXcel Research LLC
FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.
High risk -
DrugsSummit Research Peptides
FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.
High risk -
DrugsVeronvy
FDA warned Veronvy that its Elily Veronvy weight-loss drops are unapproved new drugs and falsely labeled "FDA APPROVED."
Medium -
DrugsNomida.biz
FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.
High risk -
DevicesMid-Link Testing Company, Ltd
FDA warns Mid-Link Testing over unreliable Good Laboratory Practice (GLP) safety data for medical device tests.
High risk -
DevicesSanitation & Environmental Technology Institute dba SDWH
FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.
High risk